Clinical Trial Detail

NCT ID NCT03978624
Title Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

bladder urothelial carcinoma

Therapies

Pembrolizumab

Entinostat + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.